company background image
1801

Innovent BiologicsSEHK:1801 Stock Report

Market Cap

HK$103.9b

7D

-6.4%

1Y

39.5%

Updated

29 Nov, 2021

Data

Company Financials +
1801 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

1801 Stock Overview

Innovent Biologics, Inc. operates as a biopharmaceutical company in China.

Price History & Performance

Summary of all time highs, changes and price drops for Innovent Biologics
Historical stock prices
Current Share PriceHK$71.20
52 Week HighHK$107.10
52 Week LowHK$50.20
Beta-0.11
1 Month Change2.01%
3 Month Change13.56%
1 Year Change39.47%
3 Year Change197.91%
5 Year Changen/a
Change since IPO329.43%

Recent News & Updates

Oct 11
Despite Lacking Profits Innovent Biologics (HKG:1801) Seems To Be On Top Of Its Debt

Despite Lacking Profits Innovent Biologics (HKG:1801) Seems To Be On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

1801HK BiotechsHK Market
7D-6.4%-1.9%-3.0%
1Y39.5%23.2%-5.2%

Return vs Industry: 1801 exceeded the Hong Kong Biotechs industry which returned 24.1% over the past year.

Return vs Market: 1801 exceeded the Hong Kong Market which returned -6.3% over the past year.

Price Volatility

Is 1801's price volatile compared to industry and market?
1801 volatility
1801 Average Weekly Movement7.0%
Biotechs Industry Average Movement7.9%
Market Average Movement6.8%
10% most volatile stocks in HK Market13.3%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 1801 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 1801's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20114,596Michael Yuhttps://www.innoventbio.com

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin’s lymphoma, and esophageal carcinoma.

Innovent Biologics Fundamentals Summary


Earnings & Revenue

Key profitability statistics from the latest earnings report
1801 income statement (TTM)
RevenueCN¥4.80b
Cost of RevenueCN¥1.03b
Gross ProfitCN¥3.77b
ExpensesCN¥5.34b
Earnings-CN¥1.57b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin78.62%
Net Profit Margin-32.61%
Debt/Equity Ratio15.4%

How did 1801 perform over the long term?

See historical performance and comparison

Valuation

Is Innovent Biologics undervalued compared to its fair value and its price relative to the market?

38.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1801 (HK$71.2) is trading below our estimate of fair value (HK$116.29)

Significantly Below Fair Value: 1801 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1801 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.

PE vs Market: 1801 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1801's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1801 is overvalued based on its PB Ratio (7.2x) compared to the HK Biotechs industry average (4.4x).


Future Growth

How is Innovent Biologics forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?

72.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1801 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: 1801 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 1801's is expected to become profitable in the next 3 years.

Revenue vs Market: 1801's revenue (29.4% per year) is forecast to grow faster than the Hong Kong market (12.5% per year).

High Growth Revenue: 1801's revenue (29.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1801's Return on Equity is forecast to be low in 3 years time (14.6%).


Past Performance

How has Innovent Biologics performed over the past 5 years?

-1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1801 is currently unprofitable.

Growing Profit Margin: 1801 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1801 is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare 1801's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1801 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (49.4%).


Return on Equity

High ROE: 1801 has a negative Return on Equity (-13.15%), as it is currently unprofitable.


Financial Health

How is Innovent Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: 1801's short term assets (CN¥13.4B) exceed its short term liabilities (CN¥2.2B).

Long Term Liabilities: 1801's short term assets (CN¥13.4B) exceed its long term liabilities (CN¥2.3B).


Debt to Equity History and Analysis

Debt Level: 1801 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 1801's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1801 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 1801 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Innovent Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1801's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1801's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1801's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1801's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1801's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Michael Yu (57 yo)

10.83yrs

Tenure

Dr. De-Chao Yu, also known as Michael , Ph.D. co-founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Bio...


Leadership Team

Experienced Management: 1801's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: 1801's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.


Top Shareholders

Company Information

Innovent Biologics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Innovent Biologics, Inc.
  • Ticker: 1801
  • Exchange: SEHK
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$103.931b
  • Shares outstanding: 1.46b
  • Website: https://www.innoventbio.com

Number of Employees


Location

  • Innovent Biologics, Inc.
  • 168 Dongping Street
  • Suzhou Industrial Park
  • Suzhou
  • Jiangsu Province
  • 215123
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/29 15:57
End of Day Share Price2021/11/29 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.